Merck's two-drug HIV regimen matched Gilead's blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda's patent cliff. ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK- 8591A)] in adults with HIV-1. The findings were shared in late-breaking presentations at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) being held in Denver. "We are proud to contin ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2025 As filed with the Securities and Exchange Commission on February 24, 2026 UNITED STATES OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. 126 East Lincoln ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost February 23, 20268:15 PM UTCUpdated ago By Ahmed Aboulenein U.S. Food and Drug Administration Commissioner Marty Makary speaks during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., November 10, 2025.... Purchase Licensing Rights, opens new tab Read ...

Merck creates separate oncology arm ahead of Keytruda patent loss - Invezz# Merck creates separate oncology arm ahead of Keytruda patent loss[Health & pharma]Author[Vatsala Gaur]Feb 23, 2026, 14:11 PM- Company banks on pipeline growth and recent acquisitions to offset pressure.- Leadership changes aim to prepare for Keytruda's 2028 patent expiry.- Merck splits its human-health business into oncology and specialty divisions.Merck said on Monday that it will split its human-health operations into two separate ...

Core Insights - Brown Capital Management's Small Company Fund underperformed in Q4 2025, with a decline of 1.50% compared to the Russell 2000® Growth index's gain of 1.22% [1] - The Fund's performance for the entire year of 2025 was down 11.46%, significantly lagging behind the Index's return of 13.01% [1] - The Fund's investment strategy is based on company fundamentals, which showed strong revenue and earnings growth in 2025 [1] Company Focus: Veeva Systems Inc. - Veeva Systems Inc. (NYSE:VEEV) is a technology company providing a cloud-based software platform for the life sciences industry, with a market capitalization of $29.64 billion [2] - The stock of Veeva Systems Inc. experienced a one-month return of -19.57% and a 52-week decline of 20.26% [2] - Veeva Systems was identified as a detractor from the Fund's performance in Q4 2025, despite its strong market position and innovative solutions in the life sciences sector [3] - The company's offerings include Veeva Customer Relationship Management (CRM) and Veeva Vault, which have established a dominant market position and present opportunities for growth in clinical applications [3] - Veeva's client base includes major global pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Eli Lilly, Merck, and Novartis [3]

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Core Insights - Gossamer Bio's experimental drug for a serious lung and heart condition failed to meet the primary endpoint in a late-stage clinical trial [1] Company Summary - Gossamer Bio announced the failure of its experimental drug in a late-stage study, which is a significant setback for the company [1]

Group 1 - The company is restructuring its Human Health business in anticipation of the expiration of patent protection for its major drug, Keytruda, in two years [1] - This strategic move aims to enhance operational efficiency and focus on core areas of growth within the pharmaceutical sector [1] - The decision reflects a proactive approach to mitigate potential revenue impacts from the loss of exclusivity on Keytruda, which has been a significant revenue driver [1] Group 2 - Keytruda is recognized as a blockbuster treatment, indicating its substantial market success and revenue generation capabilities [1] - The impending patent expiration poses a challenge, as generic competition may enter the market, affecting sales [1] - The restructuring may also involve exploring new therapeutic areas or partnerships to sustain growth post-Keytruda [1]

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution. ...